Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Conditions: Pancreatic Cancer
Interventions: Combination Product: TTX-030, nab-paclitaxel and gemcitabine; Combination Product: TTX-030, budigalimab, nab-paclitaxel and gemcitabine; Combination Product: Nab-Paclitaxel and gemcitabine
Sponsors: Trishula Therapeutics, Inc.; AbbVie
Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 14, 2026Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments